---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-001492"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:39:47.226121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health outlines 2026 milestones for Revita and Rejuva; cash $85.6M

## Summary
- Preliminary unaudited cash $81.5M at Dec 31, 2025; plus $4.1M from Tranche A warrant exercises on Jan 2, 2026 gives $85.6M.
- Revita: 6-month randomized REMAIN-1 Midpoint data due late Jan 2026; potential PMA filing in H2 2026.
- Rejuva: RJVA-001 first-in-human dosing expected in H2 2026 subject to CTA authorization; regulatory feedback in Q2 2026.
- Cash runway projected through early 2027 to fund all planned 2026 clinical and regulatory milestones.

## SEC filing metadata
- accession: 0001193125-26-001492
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000119312526001492/0001193125-26-001492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000119312526001492/guts-20260105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-001492
- JSON: https://secwatch.observer/filing/0001193125-26-001492.json
- Plain text: https://secwatch.observer/filing/0001193125-26-001492.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.